GlassScriptPhysician profile
Ammara Khalid
NPI 1629428537
$3,006.03
in general payments reported to CMS, 2019-2025
21 companies · $994 in 2025
The $994 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.90 · 2021: $141 · 2022: $228 · 2023: $825 · 2024: $777 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,584 · Education: $12.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,583.54 |
| Education | $12.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $711.66 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $358.12 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $323.10 | 2022-2025 | Tremfya, Stelara, Simponi |
| Axonics, INC. | $272.49 | 2021-2024 | Axonics |
| Takeda Pharmaceuticals U.S.A., INC. | $243.93 | 2023-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $177.67 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $139.11 | 2023-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $125.00 | 2022-2024 | Linzess |
| Genzyme Corporation | $94.82 | 2022-2025 | |
| Madrigal Pharmaceuticals | $81.28 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $69.43 | 2022-2024 | Ocaliva |
| Ardelyx, INC. | $67.94 | 2024-2025 | Ibsrela |
| Celgene Corporation | $66.12 | 2022-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $44.98 | 2024 | |
| Pfizer INC. | $44.45 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $40.90 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $35.22 | 2025 | Dupixent |
| Novo Nordisk INC | $32.46 | 2025 | Wegovy |
| Gilead Sciences, INC. | $30.22 | 2023 | Epclusa |
| Ipsen Biopharmaceuticals, INC | $24.53 | 2025 | Iqirvo |
| Boston Scientific Corporation | $22.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ammara Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.